Kapp Marshall B
Office of Geriatric Medicine and Gerontology, Wright State University School of Medicine, Dayton, Ohio 45401-0927.
Alzheimer Dis Assoc Disord. 1994;8(Suppl. 4):28-37.
Individuals in advanced stages of Alzheimer disease are incapable of giving or refusing legally or ethically valid consent to participation in biomedical and behavioral research protocols. Yet, many research protocols aimed at better treatment of persons with this disease can be conducted usefully only if such individuals are themselves involved as human subjects. This dilemma raises difficult issues of personal autonomy and beneficent motives. This article discusses several potential proxy decision-making mechanisms regarding research participation in light of the relevant legal and ethical concerns. The analysis is organized according to a matrix approach that takes into account procedural and substantive questions as well as the specific type of research protocol under consideration.
处于阿尔茨海默病晚期的个体无法对参与生物医学和行为研究方案给予或拒绝具有法律或伦理效力的同意。然而,许多旨在更好地治疗这种疾病患者的研究方案,只有在这些个体作为人类受试者参与其中时,才能有效地开展。这一困境引发了关于个人自主性和善意动机的棘手问题。本文根据相关法律和伦理考量,讨论了几种关于研究参与的潜在代理决策机制。分析是按照一种矩阵方法进行组织的,该方法考虑了程序和实质性问题以及所考虑的研究方案的具体类型。